(Q53558960)

15 May 2018

title

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. (English)

1 reference

15 May 2018

1 reference

1 reference

1 reference

15 May 2018

author name string

M Friedlander

1 reference

15 May 2018

M J Millward

1 reference

15 May 2018

D Bell

1 reference

15 May 2018

R Bugat

1 reference

15 May 2018

J A Moreno

1 reference

15 May 2018

L Campbell

1 reference

15 May 2018

C Varette

1 reference

15 May 2018

V Ripoche

1 reference

15 May 2018

L Kayitalire

1 reference

15 May 2018

publication date

1 December 1998

1 reference

15 May 2018

published in

Annals of Oncology

1 reference

15 May 2018

volume

1 reference

15 May 2018

issue

1 reference

15 May 2018

page(s)

1343-1345

1 reference

15 May 2018

Activity of gemcitabine in the treatment of patients with non-small cell lung cancer: a multicenter phase II study

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008469212268

7 January 2021

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008469212268

7 January 2021

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008469212268

7 January 2021

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008469212268

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008469212268

7 January 2021

Advanced breast cancer: a phase II trial with gemcitabine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008469212268

7 January 2021

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008469212268

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008469212268

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008469212268

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008469212268

7 January 2021

Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008469212268

7 January 2021

Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008469212268

7 January 2021

Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008469212268

7 January 2021

Identifiers

DOI

10.1023/A:1008469212268

1 reference

15 May 2018

release_6bih2bo43vfubljhchbat2zcme

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6bih2bo43vfubljhchbat2zcme

24 November 2022

mapped directly with Wikidata item

1 reference

15 May 2018